Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells

Respir Res. 2011 Aug 22;12(1):109. doi: 10.1186/1465-9921-12-109.

Abstract

Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by intravascular thrombus formation in the pulmonary arteries.Recently, it has been shown that a myofibroblast cell phenotype was predominant within endarterectomized tissues from CTEPH patients. Indeed, our recent study demonstrated the existence of not only myofibroblast-like cells (MFLCs), but also endothelial-like cells (ELCs). Under in vitro conditions, a few transitional cells (co-expressing both endothelial- and SM-cell markers) were observed in the ELC population. We hypothesized that MFLCs in the microenvironment created by the unresolved clot may promote the endothelial-mesenchymal transition and/or induce endothelial cell (EC) dysfunction.

Methods: We isolated cells from these tissues and identified them as MFLCs and ELCs. In order to test whether the MFLCs provide the microenvironment which causes EC alterations, ECs were incubated in serum-free medium conditioned by MFLCs, or were grown in co-culture with the MFLCs.

Results: Our experiments demonstrated that MFLCs promoted the commercially available ECs to transit to other mesenchymal phenotypes and/or induced EC dysfunction through inactivation of autophagy, disruption of the mitochondrial reticulum, alteration of the SOD-2 localization, and decreased ROS production. Indeed, ELCs included a few transitional cells, lost the ability to form autophagosomes, and had defective mitochondrial structure/function. Moreover, rapamycin reversed the phenotypic alterations and the gene expression changes in ECs co-cultured with MFLCs, thus suggesting that this agent had beneficial therapeutic effects on ECs in CTEPH tissues.

Conclusions: It is possible that the microenvironment created by the stabilized clot stimulates MFLCs to induce EC alterations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy
  • Cell Communication* / drug effects
  • Cells, Cultured
  • Chronic Disease
  • Coculture Techniques
  • Culture Media, Conditioned / metabolism
  • Endarterectomy
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology*
  • Epithelial-Mesenchymal Transition* / drug effects
  • Gene Expression Profiling / methods
  • Humans
  • Hypertension, Pulmonary / etiology*
  • Hypertension, Pulmonary / genetics
  • Hypertension, Pulmonary / metabolism
  • Hypertension, Pulmonary / pathology
  • Hypertension, Pulmonary / surgery
  • Microtubule-Associated Proteins / metabolism
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Myofibroblasts / drug effects
  • Myofibroblasts / metabolism
  • Myofibroblasts / pathology*
  • Phenotype
  • Polymerase Chain Reaction
  • Protein Serine-Threonine Kinases / metabolism
  • Pulmonary Embolism / complications*
  • Pulmonary Embolism / genetics
  • Pulmonary Embolism / metabolism
  • Pulmonary Embolism / pathology
  • Pulmonary Embolism / surgery
  • Reactive Oxygen Species / metabolism
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptors, Transforming Growth Factor beta / metabolism
  • Sirolimus / pharmacology
  • Smad Proteins / metabolism
  • Superoxide Dismutase / metabolism
  • Time Factors

Substances

  • Culture Media, Conditioned
  • MAP1LC3A protein, human
  • Microtubule-Associated Proteins
  • Reactive Oxygen Species
  • Receptors, Transforming Growth Factor beta
  • Smad Proteins
  • Superoxide Dismutase
  • superoxide dismutase 2
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type I
  • Sirolimus